Analysts Set MEDNAX Inc (MD) Price Target at $54.31
Shares of MEDNAX Inc (NYSE:MD) have earned an average rating of “Hold” from the sixteen ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $54.31.
Several research firms recently issued reports on MD. Zacks Investment Research lowered shares of MEDNAX from a “hold” rating to a “sell” rating in a research report on Friday, July 20th. Leerink Swann began coverage on shares of MEDNAX in a research report on Thursday, July 12th. They issued a “market perform” rating and a $50.00 price target for the company. Stifel Nicolaus set a $47.00 price target on shares of MEDNAX and gave the stock a “hold” rating in a research report on Thursday, August 2nd. Credit Suisse Group raised shares of MEDNAX from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $47.00 to $55.00 in a research report on Friday, August 3rd. Finally, ValuEngine raised shares of MEDNAX from a “strong sell” rating to a “sell” rating in a research report on Friday, August 3rd.
In other MEDNAX news, insider John C. Pepia sold 3,500 shares of the company’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $48.18, for a total transaction of $168,630.00. Following the sale, the insider now directly owns 30,148 shares of the company’s stock, valued at $1,452,530.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.70% of the stock is currently owned by corporate insiders.
NYSE:MD opened at $47.31 on Friday. MEDNAX has a 12-month low of $40.56 and a 12-month high of $63.04. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.52 and a quick ratio of 1.52. The stock has a market capitalization of $4.46 billion, a P/E ratio of 15.02, a price-to-earnings-growth ratio of 1.31 and a beta of 0.24.
MEDNAX (NYSE:MD) last posted its quarterly earnings results on Thursday, August 2nd. The company reported $1.07 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.07. MEDNAX had a net margin of 9.59% and a return on equity of 10.42%. The firm had revenue of $915.90 million during the quarter, compared to analyst estimates of $911.77 million. During the same quarter in the prior year, the business posted $0.85 earnings per share. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. equities analysts predict that MEDNAX will post 3.64 EPS for the current fiscal year.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Featured Article: New Google Finance Tool and Screening Stocks
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.